Tryton Medical Establishes Bifurcation Institute

December 19, 2013—Tryton Medical, Inc., (Durham, NC) announced the launch of the Bifurcation Institute, a comprehensive education resource to advance the standard of care for bifurcated coronary artery disease. Membership in the Bifurcation Institute is free and provides physicians access to e-newsletters summarizing recent clinical data and news, links to timely webcasts, and a case library that highlights the latest techniques and tips when treating bifurcation disease. Clinical symposia and educational workshops will be offered through the Bifurcation Institute.

On March 5–6, 2014, Maciej Lesiak, MD, and the Karol Marcinkowski University of Medical Sciences will host the inaugural Bifurcation Institute workshop focusing on the clinical outcomes and treatment of bifurcation lesions with the Tryton side branch stent. Dr. Lesiak is Chief of the Catheterization Laboratory at the Karol Marcinkowski University in Poznan, Poland.

In Tryton's press release, Dr. Lesiak commented, “There is a significant unmet need for education and training regarding bifurcations. In patients undergoing percutaneous coronary intervention stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75% of left main lesions are bifurcation lesions. The Bifurcation Institute aims to evolve treatment patterns and current procedural guidance to incorporate safe and effective treatment of bifurcations in daily practice.”

The company noted that the Bifurcation Institute features the results of the TRYTON investigational device exemption (IDE) coronary bifurcation trial of the Tryton side branch stent, a dedicated bifurcation device. On October 30, 2013, Tryton announced that the first results from the landmark Tryton IDE trial were presented in a late-breaking clinical trial session at the TCT 2013: Transcatheter Cardiovascular Therapeutics conference in San Francisco, California. The TRYTON pivotal trial is being conducted under an IDE from the US Food and Drug Administration.